Background: Psoriasis is a chronic immune-mediated inflammatory illness that impacts two to three percent of the global population. Cardiovascular (CV) comorbidities in cases with psoriasis may be asymptomatic and may even result in sudden mortality. Despite its widespread recognition, the N-terminal pro B-type natriuretic peptide (NT-proBNP) is not yet a standard tool for predicting (CV) outcomes in patients. Objective: The research's goal was to estimate NT-proBNP, as a predictor of CVD, in psoriasis cases and compare it with healthy non psoriatic controls and searching for any correlation among the level of serum NT-proBNP and severity of psoriasis, as defined by PASI ( Psoraisis Area and Severity Index). Patients and Methods: 50 participants with psoriasis and 40 matched healthy controls underwent laboratory test for serum level of NT-proBNP: Each participant had 3 ml of venous blood drawn, centrifuged at 3000 g for five minutes. The serum was stored at −70 degrees Celsius for further biochemical examination. Serum paraoxonase-1 concentrations were measured utilizing ELISA kits Cat. No E3041Hu. Results: In cases who had psoriasis, NT-proBNP levels were considerably greater than in the control group (median=148.5 against 53; p < 0.01). Psoriasis severity was inversely related to NT-proBNP rise. Among psoriasis cases, those with hyperlipidemia had significantly higher NT-proBNP level when compared to those with non-hyperlipidemia. Conclusion: Increased levels of NT-proBNP were seen in the studied psoriatic individuals, supporting the possibility of utilizing this biomarker to predict CV hazard in people with psoriasis.